Evolving strategies for targeted cancer therapy--past, present, and future.

@article{Wells2004EvolvingSF,
  title={Evolving strategies for targeted cancer therapy--past, present, and future.},
  author={Samuel A. Jr. Wells and Joseph R. Nevins},
  journal={Journal of the National Cancer Institute},
  year={2004},
  volume={96 13},
  pages={
          980-1
        }
}
  • S. Wells, J. Nevins
  • Published 2004
  • Medicine, Biology
  • Journal of the National Cancer Institute
Medullary thyroid carcinoma occurs most often as a sporadic malignancy, although in approximately 30% of cases, it occurs as part of the multiple endocrine neoplasia type 2 (MEN2) syndromes MEN2A and MEN2B or the related disease, familial medullary thyroid carcinoma. These three syndromes, inherited as autosomal dominant traits, are clinically characterized by near complete penetrance but variable expressivity. The thyroid malignancy is present in virtually all patients with MEN2A, MEN2B, and… Expand
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
TLDR
The data on the involvement of genes acting in the RET and RB1/TP53 pathways in MTC is reviewed, with a view to improving the efficacy of RET-targeted therapies. Expand
Alternative Options and Future Directions for Thyroid Cancer Therapy
TLDR
The unique features of thyroid cells have enabled clinicians to specifically target therapy for patients with differentiated thyroid cancers, which have led to long-term survival rates and alternative therapies using nontargeted cytotoxic chemotherapeutic agents have been largely disappointing. Expand
SAJS OCTOBER 2010.indd
127 Multiple endocrine neoplasia type 2 (MEN2) syndromes are autosomally dominant clinical associations characterised by a number of tumours, including medullary thyroid carcinoma (MTC),Expand
RET tyrosine kinase signaling in development and cancer.
TLDR
The role and mechanisms of RET signaling in development and carcinogenesis are reviewed and a deeper understanding of the molecular signaling of normal versus abnormal RET activity in cancer will enable the development of potential new treatments for patients with sporadic and inherited thyroid cancer or MEN 2 syndrome. Expand
Hereditary diffuse gastric cancer
TLDR
Consideration of total gastrectomy in CDH1 mutation carriers is recommended at an age 5 years younger than the youngest family member who developed gastric cancer, allowing curative surgery at an early stage. Expand
Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy
TLDR
It becomes strikingly obvious that inhibition of RET oncogene function can be a viable option for the treatment of MTC. Expand
Chasing the ubiquitous RET proto-oncogene in South African MEN2 families--implications for the surgeon.
  • S. Moore, M. Zaahl
  • Medicine
  • South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • 2010
TLDR
RET gene mutation carries a risk of MEN2 and MTC in all ethnic groups in South Africa, so genetic screening is important to identify and treat high-risk patients. Expand
Orbital metastasis from medullary thyroid carcinoma.
TLDR
A 46-year-old woman with known multiple endocrine neoplasia type 2A was referred for evaluation of left-sided progressive diplopia and proptosis, and a rare case of metastasis of a medullary thyroid carcinoma to the left inferior rectus muscle was postulated. Expand
CDH1 Truncating Mutations in the E-Cadherin Gene: An Indication for Total Gastrectomy to Treat Hereditary Diffuse Gastric Cancer
TLDR
CDH1 mutations in individuals from families with HDGC are associated with gastric cancer in a highly penetrant fashion and are an indication for total gastrectomy in these patients. Expand
Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
  • J. Sáez
  • Biology, Medicine
  • Anti-cancer agents in medicinal chemistry
  • 2013
TLDR
Information obtained through cytological or biopsy samples permits the study of complex metabolic or genetic pathways, thus providing researchers with a high throughput tool for elucidating changes in the global expression patterns seen in tumour cells and allowing for different therapeutic strategies in thyroid cancer which take into account the predominant altered pathways observed in these samples. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 22 REFERENCES
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
TLDR
The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential and Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma. Expand
Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
TLDR
It is proposed that a point mutation in the RET protooncogene results in the replacement of methionine with threonine within the catalytic core region of the tyrosine kinase domain, which results in dominant oncogenic activity by the RET protein. Expand
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
TLDR
This work has identified missense mutations of the RET proto-oncogene in 20 of 23 apparently distinct MEN 2A families, but not in 23 normal controls, and found that 19 of these 20 mutations affect the same conserved cysteine residue at the boundary of theRET extracellular and transmembrane domains. Expand
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
TLDR
Evidence is presented that sequence changes within the coding region of the RET proto-oncogene, a putative transmembrane tyrosine kinase, may be responsible for the development of neoplasia in these inherited disorders. Expand
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
TLDR
ZD6474, a low molecular weight tyrosine kinase inhibitor, blocks the enzymatic activity of RET-derived oncoproteins at a one-half maximal inhibitory concentration of 100 nM and might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET. Expand
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
TLDR
A novel activated oncogene resulted from the rearrangement of an unknown amino-terminal sequence to the tyrosine kinase domain of the ret proto-oncogene and was detected by transfection analysis in five out of 20 primary human thyroid papillary carcinomas and in the available lymph node metastases. Expand
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
TLDR
A missense mutation, resulting in the substitution of a threonine for a methionine at codon 918 in the tyrosine kinase catalytic domain, is reported in the germline of 26 of 28 apparently distinct families with MEN 2B. Expand
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
TLDR
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months. Expand
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
TLDR
The experience in the preclinical and clinical development of a Bcr-Abl inhibitor as a therapeutic agent for chronic myelogenous leukemia (CML) is discussed, and how this experience and other recent advances in the field could contribute to drug development for other diseases are considered. Expand
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
TLDR
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL. Expand
...
1
2
3
...